This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Abstract Objective: To determine the clinical and liver stiffness characteristics of a cohort of Chinese patients with Hepatocellular carcinoma in different stages of Barcelona clinic liver cancer. Methods: Details of 1180 patients with Hepatocellular carcinoma referred from October 2014 to November 2017 were collected retrospectively. Demographic data, etiology, clinical, and biochemical details were retrospectively analyzed. The changes of liver stiffness in different etiologies and different stages of Barcelona clinic liver cancer were especially analyzed.
| INTRODUC TI ON
Hepatocellular carcinoma (HCC) is ranked worldwide as the sixth most common malignancy. It is the second leading cause of cancer related deaths and the alarming increase in incidence has made HCC a global health concern. 1,2 According to statistics, early diagnosis of HCC is difficult due to its insidious onset. The incidence of HCC in China accounts for more than 55% worldwide. 3 Only 30%-40% of HCC patients can receive radical treatment, which seriously threatens people's life and health. 4 The highest liver cancer rates are found in East and Southeast Asia and in Middle and Western Africa. This difference in incidence of liver cancer between different geographical regions and countries is mainly attributed to difference in the incidence of underlying risk factors. 5 A substantial amount of patients are diagnosed at a later stage of the disease, which may preclude curative treatment options.
Therefore, it is very necessary to describe the clinical characteristics of HCC patients in different regions and stages, which is of great value for the early detection, early diagnosis, early treatment, reduction of morbidity, and improvement of prognosis of patients.
Liver stiffness measurement (LSM) using transient elastography has been introduced as a promising noninvasive method for assessing the degree of liver fibrosis. Moreover, transient elastic imaging detector is one of the most widely validated noninvasive tools to detect early liver cirrhosis in various chronic liver diseases. Elasticity imaging has been reported to be useful for the diagnosis and characterization of various tumors, which are usually stiffer than normal tissues. Recent studies on liver stiffness indicate that LSM may be useful in screening for HCC, and several studies have investigated the prognostic role of LSM in the noninvasive assessment of the risk for HCC development. 6 In this study, we aimed to evaluate the significant clinical characteristics and to assess differences of biochemical details with HCC in different stages of Barcelona clinic liver cancer (BCLC). Moreover, the aim of this study was to investigate whether LSM assessed by transient elastography shows a significant correlation with HCC. 7 The patients were divided into four groups according to BCLC stage at admission. 8 The study was approved by the ethics committees of participating hospitals.
| MATERIAL S AND ME THODS

| Objects of the study
The clinical parameters including age, gender, etiology, diabetes, and tumor characteristics were obtained. Laboratory investigations including alanine aminotransferase (ALT), alkaline phosphatase (AKP), prothrombin time (PT), alpha-fetoprotein (AFP), and γ-glutamyltransferase (γ-GT) and liver stiffness measurement (LSM), respectively, were obtained.
| Statistical treatment
Epidata 3.1 dual input was used for data entry. Data were analyzed using SAS software version 9.4. Qualitative data were expressed in proportion and chi-square test was used. Quantitative data were expressed by mean and standard deviation, and the comparison between groups and within groups was conducted by a single factor ANOVA test. A P-value of <0.05 was considered statistically significant.
| RE SULTS
| Patient inclusion and clinical characteristics
A total of 1180 patients diagnosed with HCC were included in the study. The mean age was 60.33 ± 9.11 (range 24-84) years, with a male preponderance (n = 922; 78.25%). The overall male to female (M/F) ratio was 3.57 (922/258) ( Table 1) . Compared with males, females were significantly more likely to be ≥61 years ( Figure 1 ).
There were 787 patients (66.69%) with HBV-associated HCC and 217 patients (18.39%) with HCV-associated HCC. Alcohol was the cause for HCC in 176 (14.92%) ( Table 1 ).
The proportion of patients with HBV-associated HCC in 41-60 years was higher than in ≥61 years. The proportion of patients with HCV-associated HCC in 41-60 years was lower than in ≥61 years. HBV-related HCC was significantly more likely to be younger than HCV-related HCC ( Figure 2 ).
K E Y W O R D S
alcoholic liver disease, alpha-fetoprotein, hepatocellular carcinoma, liver stiffness measurement, viral hepatitis
In this study, all patients aged ≥18 years were enrolled as inpatients.
Overall, the commonest age was ≥61 years, which were 599 patients (50.56%), followed by 41-60 years in 572 patients (47.83%; Table 1 ).
In addition, in this cohort, 928 (78.25%) patients had diabetes ( There was no statistically significant difference in the four groups of the etiology, age, gender, and diabetes history (P > .05; Table 1 ).
Tumor characteristics.
The number of patients with a single tumor was 608 (51.53%), and the remaining patients had multinodular (572 patients, 48.47%).
( 
| Etiological distribution
The age of male HCC patients according to etiology for 41-60 years was as follows: 338 (70.42%) patients with HBV infection, 45 Chi-square test results showed that the etiology of male patients was statistically different in different age groups (P = .001). There was no significant difference in etiology of female patients in different age groups (P = .331; Table 3 ).
| Age distribution
In male patients, the majority of HBV-induced HCC patients were Chi-square test results showed that male HCC patients were distributed differently in different etiological age groups (P = .001).
There was no significant difference in age distribution of different etiologies among female HCC patients (P = .331; Table 4 ).
| Sex distribution
The age at onset of HBV-induced HCC was 41-60 years old, of which 85.57% were males and 14.43% were females. It was followed by the age group of ≥61 years old, of which 75.38% were males and 24.62% were females. The second cause of HCC was HCV, which was more common in the age group of ≥61 years old, with 52.94% males and 47.06% females. Alcohol was the least common cause of HCC patients, most of whom were 41-60 years old, of which 96.04%
were males and 3.96% were females.
Chi-square test results showed that the gender distribution of HBV infection in different age groups was different (P < .001). There was no significant difference in gender distribution of HCV infection and alcohol-related in different age groups (P = .663 and P = .851; Table 3 ). AFP was significantly different in stages A, C (P < .001) and D (P = .008). It was found that there was no significant difference between stages C and D of HCC (P = .638; Table 5 ).
| Comparison of clinical examination indicators
| Distribution of LSM value
ANOVA analysis showed that the overall LSM values among the four BCLC stages were 23.19 ± 16.32 kPa, 28.00 ± 18.84 kPa, 32.54 ± 21.85 kPa, and 33.06 ± 21.61 kPa, respectively. LSD test showed statistically significant difference among the four stages (P < .001).
In stages A and B, the increase of LSM caused by alcohol was higher than that of HBV or HCV infection (stage A: F = 16.77, P < .001 and stage B: F = 4.84, P = .004). There was no statistically significant difference among the four BCLC stages in alcohol-related HCC patients (F = 0.326 and P = .807). There was a statistically significant difference among the four BCLC stages in HBV-infected HCC patients (except between groups C and D). There was a statistically significant difference among the four BCLC stages in HCV-infected HCC patients (between stages A and B, C, D, between stages B and D). (Table 6 ).
| D ISCUSS I ON
In this retrospective, multicentre, and observational cohort study, we investigated the clinical characteristics of HCC patients, compared the incidence rate from gender, age, and etiology, and refined the epidemiological characteristics. Among the 1180 cases, it was found that the youngest individual was 24 years old, as well as with a male predominance. 9 cases were ≤40 years old, and the peak age ranged >40 years old, with 572 cases aged 41-60 years old and 599 cases aged ≥61 years old. Previous studies have shown that this may be related to the progression of liver fibrosis with age. 9 Among the studied cases, there were 395 (69.06%) cases of HBV-related HCC patients aged 41-60, of which 338 were males and 57 were females, and 76 (13.29%) cases of HCV-related HCC patients, including 45 males and 31 females. There were 390 (65.11%) cases of HBV infection ≥61 years old and 136 (22.70%) cases of HCV infection. It was found that HBV-related HCC was mostly found in 41-60 years old, while HCV-related HCC was mostly in ≥61 years old. This finding may be explained that HBV is transmitted vertically in the perinatal period, whereas HCV is more infected at a later stage in life, and therefore, patients with HBV-related HCC tended to be significantly younger than patients with HCV-related HCC. 10 Our data showed that chronic viral hepatitis was the major risk factor contributing to the development of HCC and majority were males. This study revealed that HCC was more prevalent in males, which is in agreement with previous studies, 16, 17 as well as other local and regional studies. 18, 19 In addition, the finding that females were significantly older than males might also refect a course in disease progression. Previous studies have shown that the liver fibrosis status of women changes with age, which may be due to changes in the reproductive status, 20 Therefore, less treatment measures will affect the prognosis of patients. We again recommend regular follow-up of patients with liver disease to improve early diagnosis.
AFP is a useful diagnostic marker for HCC, and roughly 50%-70% of adults with HCC have increased levels of AFP. 23, 24 In this study, AFP was found to be related to HCC progression from stage A to stage D and was basically positively correlated, which suggests that higher serum levels of AFP were more likely to present with advanced stage HCC with severe liver dysfunction and compromised performance status. γ-GT mainly exists in liver cell membrane and microsome. Data have indicated that γ-GT serum level can be used to evaluate liver fibrosis and injury as a sensitive and accurate biomarker. 25 γ-GT increases moderately or highly in patients with viral hepatitis, liver cirrhosis, alcoholic hepatitis, and primary or metastatic liver cancer. In this study, it is found that γ-GT had an increasing trend with advanced stage HCC and had statistical significance.
In addition, SandraL 26, 27 and other studies have found that AKP is closely related to liver fibrosis. This study showed that AKP level gradually increased with advanced stage HCC from stage A to stage D, with statistical differences.
Many literatures have shown that liver cirrhosis is the main risk factor for liver cancer. 28, 29 accurately diagnose liver fibrosis, but also predict liver cancer effectively. 30 The results of this study showed that the LSM value gradually increased in the progression of HCC patients from stage A to stage D. Further comparison showed that the LSM value of patients with alcohol-associated HCC was significantly higher than that of HBV-associated group and HCV-associated group, whether in stage A or stage B. However, the difference of LSM values between BCLC stages was not significant in patients with alcohol-associated HCC.
In contrast, in patients with viral hepatitis, no matter HCC was caused by hepatitis B or hepatitis C, LSM value increased with the progress of HCC stage, and it was statistically significant. Therefore, patients with viral hepatitis still need active etiological treatment to minimize or even eliminate viral replication.
Therapeutic approaches for HCC include partial hepatectomy, liver transplantation, and interventional methods such as transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT), or local ablative methods. For advanced and metastatic HCC, pharmacological treatment options have largely expanded over recent years. 28 Surgical treatments, TACE, and Radiofrequency ablation (RFA) are best options to achieve optimal survival rates in the long-term, and there is still a need for improvement of current surveillance methods for earlier detection of HCC to facilitate those curative treatments for most of the patients.
In summary, the peak age of incidence of HCC was found to be >40 years old. HBV-associated HCC patients are often younger than HCV-associated HCC patients. Male is a high incidence pop- The results of this study are limited by its retrospective design and need to be further confirmed by wider prospective and multicenter studies.
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